<DOC>
	<DOCNO>NCT00778128</DOCNO>
	<brief_summary>At step 1 , patient advance solid tumor receive CP-4126 capsule follow dose escalation schedule maximum tolerate dose reach . At step 2 , 20 patient randomize . They receive day 1 8 double cross design either oral CP-4126 recommend dose gemcitabine 1000mg/m2 intravenously . At step , schedule treatment day 1 , 8 , 15 q4w complete response disease worsening/ progressing . All treatment step 2 oral CP-4126 .</brief_summary>
	<brief_title>A Phase I Clinical Study Oral CP-4126 Patients With Advanced Solid Tumour</brief_title>
	<detailed_description>This multicentre clinical study conduct Belgium The Netherlands . The study phase I divide 2 step : The first step dose escalation define RD . At second step PK profile oral CP-4126 compare PK profile IV gemcitabine . In addition , study conduct characterize tolerability oral CP-4126 , evaluate bioavailability , make preliminary assessment antitumor activity patient solid tumour .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . Histologically cytologically confirm solid tumour diagnosis 2 . Locally advanced metastatic disease , know effective treatment 3 . Performance Status 0 2 accord ECOG ( Eastern Cooperative Oncology Group ) Performance Status 4 . Age 18 year 5 . Life expectancy &gt; 3 month 6 . Adequate hematological biological function : 7 . Signed informed consent 1 . Symptomatic brain metastasis 2 . Current peripheral neuropathy grade &gt; 1 accord National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) Version 3.0 3 . Radiotherapy 30 % bone marrow single dose 8 Gy le one week prior study treatment upper GI tract 4 . Mucositis upper digestive tract , include stomatitis 5 . Participation another therapeutic clinical study within 30 day enrolment clinical study 6 . Previous anticancer therapy ( chemotherapy , hormone therapy immunotherapy ) within 30 day prior first dose oral CP4126 [ 6 week mitomycin C BCNU ( = carmustine ) CCNU ( =lomustine ) ] 7 . Requirement concomitant treatment nonpermitted medication include alternative drug high dos vitamins 8 . History allergic reaction gemcitabine 9 . Presence serious concomitant systemic disorder incompatible clinical study ( e.g . uncontrolled intercurrent illness include ongoing active infection ) 10 . Presence significant central nervous system psychiatric disorder ( ) would hamper patient 's compliance 11 . Pregnant breast feed woman 12 . Absence adequate contraception male female fertile patient duration study ; also six month last treatment 13 . Known positive status HIV and/or hepatitis B C 14 . Any reason , investigator 's opinion , patient participate 15 . Condition impair ability swallow pill 16 . Coeliac disease lipid malabsorption syndrome 17 . Drug and/or alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>CP-4126</keyword>
	<keyword>Cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Solid tumour</keyword>
	<keyword>Gemzitabine</keyword>
	<keyword>Gemzar</keyword>
</DOC>